Prospectus
Filed with ASX · · 59 pages · English
Summary by 6ix AI
PainChek Ltd has filed a prospectus detailing a non-renounceable entitlement offer for eligible shareholders, allowing them to acquire new shares and options at a specified price. The offer aims to raise funds for various initiatives, including expansion in the aged care sector and technology development. The prospectus outlines the risks associated with the investment and emphasizes that the securities offered are speculative in nature. Eligible shareholders must apply for the new securities before the closing date specified in the document.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/prospectus-22
Story so far
Earlier from PainChek
- Underwritten Entitlement Offer to raise AUD $5.1million
- PCK submits application for Adult App FDA De Novo clearance
- PCK expands market reach with BESTMED reseller agreement
- Positive study results pave way for PainChek FDA submission
- PainChek Adult app FDA De Novo submission update
Later from PainChek
- PainChek Implementations, Market and International Expansion
- PainChek completes Entitlement Offer raising AUD $5.1 m
- R&D Tax Refund, FDA Review of Adult App & Infant App Launch
- PainChek partners with Eldermark to expand US market reach
- PainChek has productive final FDA De Novo clearance meeting
Follow PainChek into a list and get an email when it puts out news.
Follow PainChek